Amended Current Report Filing (8-k/a)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

(Amendment No. 1)

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 1, 2016

 

 

SYNDAX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		001-37708		32-0162505
(state or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)
400 Totten Pond Road, Suite 110 Waltham, Massachusetts				02451
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: [phone]

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Explanatory Note

On July 6, 2016, Syndax Pharmaceuticals, Inc. (the “ Company ”) filed a Current Report on Form 8-K (the “ Original Report ”) to report that the Company entered into a license agreement (the “ Agreement ”) with UCB Biopharma Sprl. This Current Report on Form 8-K/A amends the Original Report solely to file the Agreement as an exhibit hereto. The other disclosures made in the Original Report remain unchanged.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.		Description
10.1		License Agreement, by and between the Company and UCB Biopharma Sprl, dated July 1, 2016.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

SYNDAX PHARMACEUTICALS, INC.
By:		/s/ Briggs W. Morrison, M.D.
		Briggs W. Morrison, M.D.
		Chief Executive Officer

Dated: October 7, 2016

---

EXHIBIT INDEX

 

Exhibit No.		Description
10.1		License Agreement, by and between the Company and UCB Biopharma Sprl, dated July 1, 2016.